NEW YORK — Jonathan M. Sedgh, a prominent figure in the legal battle against pharmaceutical and medical device giants, has garnered significant attention for his role as a product liability lawyer at Morgan & Morgan. Sedgh is renowned for filing landmark lawsuits on behalf of clients who have suffered due to insufficiently tested or disclosed side effects of medical products.
In August 2023, Sedgh made headlines when he and his team initiated the first lawsuit concerning the drugs Ozempic and Mounjaro, which was filed in Louisiana. The case revolves around a woman who developed gastroparesis, a severe condition that paralyzes the stomach, allegedly due to her use of these medications. The lawsuit accuses the manufacturers of failing to adequately warn consumers about the potential risk associated with these drugs.
Throughout his career, Sedgh has played pivotal roles in numerous litigations that have had profound impacts on public health policies and corporate accountability. His efforts have been vital in cases against manufacturers of defective pharmaceuticals and medical devices, as well as pursuing justice for victims of sex trafficking and childhood sexual abuse.
His legal prowess extends beyond the courtroom. Sedgh has participated in over a dozen multidistrict litigations and coordinated state-court actions, handling thousands of cases. His dedication to guiding clients through the complex landscape of legal proceedings from filing to trial or settlement negotiations has established him as a trusted advocate.
Sedgh’s commitment and success have not gone unnoticed in the legal community. He has received several awards, such as the National Trial Lawyers Top 40 Under 40 and Top 100. His expertise has also made him a sought-after speaker and panelist at national seminars on mass tort and product liability.
One of Sedgh’s most significant legal victories includes a groundbreaking $9 billion jury verdict. He represented a client who developed bladder cancer after taking the Type 2 diabetes medication Actos, which was co-manufactured by Eli Lilly and Takeda Pharmaceuticals. The lawsuit alleged that the firms failed to warn the public about the cancer risks and continued to market the product despite known dangers.
Additionally, in November 2021, Sedgh was part of a legal team that secured a substantial settlement for an Army sergeant. The case against 3M alleged that the company’s defective Combat Arms earplugs caused the plaintiff to suffer hearing loss. The verdict included $816,395 in compensatory damages and $12.245 million in punitive damages.
In another significant role, Sedgh was appointed to the Plaintiffs’ Leadership Committee in the multidistrict litigation concerning the Abbott infant formula recall in September 2022. This legal action consolidated several lawsuits related to health issues in children who consumed contaminated formula from Abbott’s Michigan facility.
Sedgh is admitted to practice in various jurisdictions, including the Southern, Eastern, and Northern District Courts of New York. He is affiliated with multiple prestigious legal organizations, such as the American Association for Justice and the New York State Bar Association.
Jonathan M. Sedgh’s career underscores the significant impact diligent legal advocacy can have on public health and safety. His work continues to influence the broader legal strategies employed in pharmaceutical and medical device litigation across the United States.
Disclaimer: This article was automatically written by Open AI and the people, facts, circumstances, and story may be inaccurate. Any article can be requested removed, retracted, or corrected by writing an email to contact@publiclawlibrary.org.